Key result
Digoxin toxicity affects ~1% of treated CHF patients and requires early recognition and antibody fragments.
Why the study?
How is digoxin toxicity diagnosed and managed in clinical practice?
How is digoxin toxicity diagnosed and managed in clinical practice?
Digoxin toxicity remains a clinical diagnosis where blood levels do not always correlate with symptoms, and life-threatening cases require prompt treatment with digoxin-specific antibody fragments.
Answers are grounded in this paper and cite their sources.
Supports vigilance for toxicity in digoxin-treated HF; leaves open prospective trials on current incidence and management.
Cardiac glycosides, including digitalis and digoxin, have long-standing use in clinical practice. Digoxin has a half-life that varies from 36 to 48 hours, which may increase in cases of renal failure. Approximately 1% of Congestive Heart Failure patients treated with digoxin develop toxicity. The clinical features of toxicity are often non-specific. Diagnosis is difficult and usually made clinically, as levels of digoxin in the blood do not necessarily correlate with toxicity. Treatment involves early recognition and the administration of antibodies specifically against digoxin also known as Fab fragments. Digoxin concentration does not necessarily correlate with clinical symptoms of toxicity however digoxin concentrations may be used for calculating the amount of antidote therapy. Digoxin-specific antibody fragments are used when there is a risk of a life-threatening arrhythmia.
No takes yet. Share an insight, caveat, or question.
Ibrahim et al. (2021) conducted a review in Digoxin toxicity. Digoxin-specific antibody fragments (Fab fragments) was evaluated. Digoxin toxicity occurs in approximately 1% of treated congestive heart failure patients and is managed with early recognition and administration of digoxin-specific antibody fragments.
Synapse has enriched 10 related papers. Consider them for comparative context: